Model explainability compliance means being able to show, in terms a specific reviewer understands, why an AI model produced a given output, and to back that up with documentation that holds up under review. In U.S. life sciences there is no single "explainability law." The expectation comes from FDA guidance and principles that tie the depth of explanation to the model's context of use and risk. This guide covers what those documents say, what to document, which methods help, and how to build the practice into daily operations without overstating what you have achieved.
TL;DR
- Explainability is about communicating why a model reached a conclusion to a particular audience. It is related to, but not the same as, interpretability and transparency.
- FDA's January 2026 guiding principles call for a risk-based approach: the more a model influences a regulatory decision, the more validation, oversight and documentation it needs.
- Document data provenance, analytical decision steps, context of use, performance, limitations and monitoring, in a traceable way that fits GxP.
- Explanation methods have limits, including accuracy gaps and privacy leakage, so choose them for the audience and the risk, not for convenience.
- Treat explainability as an operating process with owners, review cycles and change control, not a one-time report.
Table of Contents
- What model explainability actually means
- What U.S. regulators say about AI explainability
- Which biotech AI use cases fall in scope
- What to document so decisions are traceable
- Explainability methods and their limits
- Validation, bias, oversight, monitoring and model changes
- Our perspective: explainability is an operations problem
- A practical sequence for building explainability in
- How we help biotech teams operationalize this
- FAQ
- Sources
What model explainability actually means
The terms get mixed up, which causes real problems in audits and vendor conversations. A Royal Society policy briefing frames explainability as the ability to communicate why or how a conclusion was reached in terms a specific audience can understand. Interpretability, by contrast, usually implies that the model's internal mechanics can be understood by design. Transparency refers to how accessible the underlying data, algorithms or processes are.
For a clinical operations lead, that distinction is practical:
- Explainability is what you tell a reviewer, an auditor or a site coordinator about why the model flagged a site, drafted a section or ranked a risk.
- Interpretability is a property of the model itself. A simple scoring model may be interpretable on its face. A deep network usually is not.
- Transparency is whether the training data, code and processing steps can be inspected and traced.
FDA uses similar language for devices. In its transparency principles for machine learning-enabled medical devices, explainability is the degree to which a device's logic, meaning the basis for a decision or action, can be explained in a way a person can understand.
Expect inconsistency in how others use these words. A 2022 review in Artificial Intelligence Review notes that some authors treat interpretability as an inherent property and explainability as post-hoc analysis, while others use them interchangeably. Define your terms in your own SOPs and validation plans so that everyone, including vendors, works from the same definitions.
What U.S. regulators say about AI explainability
There is no standalone statute titled "model explainability." What exists is a set of FDA documents and enforcement signals that together define what reviewers expect.
FDA's risk-based principles for drug development
The January 2026 Guiding Principles of Good AI Practice in Drug Development recommend a risk-based approach, with validation and oversight proportionate to the context of use and the model's risk. They also ask for plain-language information for users and patients about an AI technology's context of use, performance, limitations, underlying data, updates, and interpretability or explainability.
That last point matters. Explainability here is not only a technical artifact for data scientists. It is something that must be communicated in accessible language to the people affected by the model.
FDA's credibility assessment for regulatory decision-making
FDA's January 2025 guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, addresses AI used to produce information or data that supports decisions about the safety, effectiveness or quality of drugs. Such use is subject to a risk-based credibility assessment for its particular context of use.
In practice, "credibility" is where explainability lives. If your model's output feeds a submission, you need to be able to show why a reviewer should trust it for that specific purpose.
Device-side transparency
For software that is itself a medical device, FDA, Health Canada and the UK's MHRA describe it as good practice to share information on the underlying technology, training and testing data, and clinical-study summaries, including known biases, failure modes and confidence intervals, so users can assess the device critically. The guiding principles are a useful template even for internal tools, because they show the level of candor reviewers are used to seeing.
Enforcement signals on claims
The FTC has been direct about claims. In a 2024 closing letter to HeHealth Inc., the agency stressed that companies need competent and reliable scientific evidence, evaluated by qualified persons and accepted in the profession, to substantiate health and safety claims about AI-powered medical applications. If you describe a model as "explainable," "validated" or "unbiased" in marketing or investor material, you need the evidence behind each word.
A note on older sources: NIST's 2021 draft report on trust in AI, Trust and Artificial Intelligence, identified explainability, safety and accountability among the characteristics most pertinent to user trust. NIST has since withdrawn that draft, so use it as background on why explainability matters, not as a compliance reference.
Which biotech AI use cases fall in scope
Not every AI tool carries the same burden. A useful way to sort your portfolio is by what the output touches.
| Use case | Typical question a reviewer asks | Explainability burden |
|---|---|---|
| AI generating data or analyses that support safety, effectiveness or quality decisions | Is the model credible for this context of use? | High: full credibility assessment, traceability, validation |
| AI-based drug development tools, such as histology measurement | Is the tool qualified for its stated purpose? | High: qualification evidence for the specific use |
| Regulatory drafting assistance with human review | Who verified the content and from what source material? | Moderate: source traceability, review records, change control |
| Clinical site selection and activation support | Why were these sites prioritized? | Moderate: rationale a project lead can explain and challenge |
| Internal knowledge search and summarization | Is the retrieved material accurate and current? | Lower, but document data sources and limits |
The FDA has begun qualifying drug development tools that incorporate AI. The agency's Spring 2026 C3TI newsletter cites the AI-Based Histologic Measurement of NASH (AIM-NASH) as an example. It is a reminder that AI can earn a formal regulatory standing, and that the path runs through evidence tied to a defined purpose.
The table is a triage aid, not a regulatory classification. Your context of use, not the tool category, sets the burden, so confirm placement with your quality and regulatory leads.
What to document so decisions are traceable
The January 2026 principles point to a clear documentation set. Teams should record data source provenance, analytical decision steps and processing methods in a traceable and verifiable manner, aligned with GxP requirements. They should also cover the context of use, performance monitoring, identified limitations, risk management strategies and validation of predictive performance, as laid out in the FDA principles.
Turned into a working checklist:
- Context of use statement. What decision the model informs, who uses the output, and what happens if it is wrong.
- Data lineage. Where training, validation and operational data came from, how they were processed, and who approved them.
- Decision trail. For each output, the inputs, the model version and the processing steps, so a reviewer can reproduce or challenge the result.
- Performance evidence. Accuracy, reliability and robustness measured on data that is fit for the context of use.
- Known limitations. Populations, document types or conditions where the model underperforms, and the controls you apply there.
- Human oversight record. Who reviewed what, what they changed, and what they rejected.
- Change history. Updates, retraining events and the re-validation you ran after each one.
- Plain-language summary. A short, accessible description for users that covers the items above.
If your documents are not yet classified for GxP relevance, start there. Our practical guide to GxP document classification shows how U.S. teams can sort records so the right controls attach to the right files, and our 7-step GxP validation lifecycle for AI walks through how QA and regulatory teams can structure validation around the evidence above.
Explainability methods and their limits
There is no universal technique that makes every model explainable. FDA's discussion paper on AI and machine learning in drug development mentions selecting parsimonious models, which means simpler ones that balance performance against explainability, and using feature-based explanations. It notes that feature-based explanations can have limitations, including potential privacy leaks about training data. It lists accuracy, reliability and robustness among the evaluation metrics, validated with data that is fit for the context of use.
Three trade-offs deserve a plain statement in your documentation.
Accuracy versus understandability. NIST researchers note that black-box methods are often the most accurate but hard to explain, and they are exploring combinatorial methods that derive rule-based explanations, such as "if A and B, then X," from complex functions. If a simpler model meets the performance need for your context of use, it is often the easier one to defend.
Faithfulness versus simplicity. An overview of the field frames the central challenge as producing explanations accurate enough to defend an action and simple enough for people to understand. A tidy explanation that does not reflect what the model actually did is a liability. Test explanations against model behavior, not only against reader satisfaction.
Explanation versus privacy. Research presented at FTC PrivacyCon 2020 on privacy risks of model explanations found that explanations revealing statistical information about decision boundaries can leak sensitive information about whether specific data points were in the training set. When models touch patient-level data, involve your privacy officer before choosing an explanation method.
Choose the method by audience, too. A clinician reviewing a flagged safety signal needs a different explanation than a QA auditor tracing a draft section or an executive reviewing a timeline forecast. The goal is the same, a defensible reason, but the format differs.
Validation, bias, oversight, monitoring and model changes
Explainability does not end at go-live. The FDA principles call for risk-based quality management, scheduled monitoring and periodic re-evaluation to catch issues such as data drift, along with plain-language communication of updates, as described in the January 2026 guidance. The FDA's CDER discussion paper adds that real-world performance monitoring is critical, and that later assessments such as postmarket safety monitoring can feed back into retraining and risk management.
Build these controls into the operating model:
- Validation. Scale effort to risk. A model that drafts a first-pass summary for human review needs less than one that scores data going into a submission.
- Bias checks. Record the populations and document types in your data, and test for performance differences before and after updates.
- Human oversight. Define who can override the model, what they must check, and how overrides are logged.
- Monitoring. Set thresholds for drift and performance, assign an owner, and schedule re-evaluation.
- Change control. Treat retraining, prompt changes and data refreshes as changes that trigger a proportionate review.
For clinical operations, monitoring is where this gets concrete. Our write-up of a 90-day partnered pilot for AI-enabled risk-based monitoring shows how a bounded pilot can generate the performance evidence you need before scaling.
Our perspective: explainability is an operations problem
Most explainability programs stall because they are owned by one function. Data science builds the explanation, quality asks for the documentation, regulatory worries about the submission, and clinical operations just wants the tool to work. Each team solves its own piece, and nobody owns the whole chain from data to decision to record.
We start from the opposite end. We look at the strategic goal, such as a submission milestone or a site activation target, and work backward to find where the process breaks. Often the bottleneck is not the model. It is the missing evidence trail, the unclear review step, or the document nobody classified.
That is why we embed senior expert teams inside live operations instead of handing over software or a list of recommendations. Our approach is designed to redesign workflows around your specific regulatory and scientific needs, put governance and adoption support in place, and keep monitoring after launch. Explainability then becomes a by-product of how work is done: every AI-assisted step has an owner, a source and a record.
We would rather help a team document a modest, well-governed use case properly than promise a sweeping one it cannot defend. Reviewers reward clarity about context of use, and so do investors.
John
A practical sequence for building explainability in
The open question for most teams is how to make progress without claiming more than the evidence supports. This sequence keeps the work proportionate.
- Inventory your AI uses. List every model and AI-assisted workflow, who uses it and what decision it touches. Include tools adopted informally.
- Define the context of use for each. One sentence on purpose, one on the decision supported, one on the consequence of error.
- Rank by risk. Use the context of use to decide which uses need full credibility assessment and which need lighter controls. Our guide to what AI governance platforms really mean for biotech teams can help you decide what tooling, if any, supports this step.
- Fix the evidence trail first. Before refining any explanation technique, make sure data sources, versions and review records exist and are retrievable.
- Pick explanation methods by audience. Match the format to the reviewer, and test the explanation against actual model behavior.
- Write the plain-language summary. If a site coordinator or patient-facing team cannot read it, rewrite it.
- Set monitoring and change triggers. Name the owner, the thresholds and the re-validation steps.
- Review your claims. Check every statement in decks, websites and filings about "explainable," "validated" or "compliant" against the evidence on file. The FTC's expectation of competent and reliable scientific evidence applies to the words you choose.
Where regulatory writing is in play, it helps to know the line between automation and judgment. Our overview of where AI can help in regulatory affairs and what must stay human draws that line for drafting and review tasks. For clinical workflows, the biotech playbook for redesigning clinical workflow with governed AI shows how to embed review steps so that explanation is captured as work happens.
Common mistakes to avoid
- Treating a vendor's feature description as your validation evidence.
- Documenting the model but not the human review that surrounds it.
- Retraining or swapping a model version without a change record.
- Using an explanation method that has never been checked against model behavior.
- Describing a tool as "compliant" when no regulator has assessed it for your context of use.
How we help biotech teams operationalize this
If your team has AI in use but the evidence trail is patchy, we can help close the gap. Our embedded operating partnership starts with a diagnostic of where your processes slow down, then redesigns the affected workflows with governed automation, expert-led adoption and ongoing monitoring across clinical, regulatory and executive operations. You can see how we work on our partnership page, and how we approach safeguards on our trust page.
If you are weighing whether to build this capability internally, our decision framework for a fractional AI partner versus an internal team lays out the criteria. For a broader view of where teams stand, the State of AI in Biotech 2026 report is a good place to benchmark.
FAQ
Is explainability legally required for AI in drug development?
There is no single U.S. statute that mandates it by that name. FDA's guidance and principles ask for a risk-based credibility assessment tied to the context of use, and they include explainability among the information to communicate. The higher the model's influence on a regulatory decision, the more you should expect to show. Confirm specifics for your program with your regulatory affairs lead.
What is the difference between explainability and interpretability?
Explainability is communicating why a model reached a conclusion to a specific audience. Interpretability usually means the model's internal workings are understandable by design. Some authors use the terms interchangeably, so define them in your own procedures.
Do SHAP or LIME outputs satisfy regulators on their own?
No method satisfies review by itself. Feature-based explanations can have limitations, including potential privacy leaks about training data, and they must be validated against the model's behavior. They work best as one part of a documented package that includes context of use, performance evidence and monitoring.
What should we document first?
Start with the context of use and the data lineage. Those two records anchor everything else, including validation scope, risk ranking and the plain-language summary. Then add the human review record and the change history.
How often should we re-evaluate a deployed model?
FDA's principles call for scheduled monitoring and periodic re-evaluation to catch issues such as data drift. The right interval depends on the model's risk and how quickly your data changes, so set it in your quality plan and revisit it after any model update.
Sources
- Explainable AI: the basics, Royal Society policy briefing
- Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles, FDA
- Trust and Artificial Intelligence, NIST draft report
- A global taxonomy of interpretable AI, Artificial Intelligence Review
- Guiding Principles of Good AI Practice in Drug Development, FDA
- FTC closing letter to HeHealth Inc.
- Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, FDA
- C3TI Newsletter, Spring 2026, FDA
- Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products, FDA
- Assured Autonomy through Combinatorial Methods, NIST
- Explaining Explanations: An Overview of Interpretability of Machine Learning
- On the Privacy Risks of Model Explanations, FTC PrivacyCon